Trials / Unknown
UnknownNCT04190667
Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer
A Study on the Homologous Recombination Deficiency Status in Chinese Population With Epithelial Ovarian Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,300 (estimated)
- Sponsor
- Lei Li · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The homologous recombination deficiency (HRD) status in Chinese population with epithelial ovarian cancer (EOC) is little known. This study would recruit 1300 Chinese EOC patients. A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status. The HRD model is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients.
Conditions
- Epithelial Ovarian Cancer
- Chinese
- Homologous Recombination Deficiency
- BRCA1 Mutation
- BRCA2 Mutation
- Prognosis
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Genomic testing | A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A）, ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30（EMSY）, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status. |
Timeline
- Start date
- 2019-12-07
- Primary completion
- 2021-12-07
- Completion
- 2022-12-07
- First posted
- 2019-12-09
- Last updated
- 2019-12-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04190667. Inclusion in this directory is not an endorsement.